US Drug Supply Chain
The security of the pharmaceutical supply chain is vital to protecting public health. Illegitimate drugs can reach patients if the supply chain is not secure. We work with boards of pharmacy, regulators, and industry partners to help prevent that.
Protecting the Drug Supply Chain
We work to support the boards of pharmacy and educate and protect the public about state drug importation plans by:
-
Providing guidance to state and federal governments and other policy makers on the risks associated with prescription drug importation and the necessary regulatory oversight process to help mitigate those risks.
-
Working with state and federal regulators to implement the Drug Supply Chain Security Act (DSCSA), including providing education and other tools to regulators and supply chain participants to assist in implementation.
-
Educating the public about the risks associated with purchasing prescription drugs from unknown sources online and through social media.

Supporting DSCSA Implementation
The Drug Supply Chain Security Act requires electronic, interoperable product tracing at the package level, across the pharmaceutical supply chain. Passed under the Drug Quality and Security Act of 2013, a 10-year timeline for full implementation of the DSCSA requirements was established. In November of 2023, FDA announced a stabilization period would go into effect for trading partners to comply with DSCSA regulations. FDA is continuing to work toward implementation, hosting several town halls throughout 2025 to discuss progress with stakeholders in the supply chain.
For several years before the implementation deadline, we have worked with an industry-wide network of regulators and stakeholders to create a solution to support implementation of the requirements. We conducted pilot programs to uncover interoperability gaps between industry participants and state regulators, as well as to understand business requirements and the tools and processes needed to meet DSCSA requirements.
Pulse by NABP
In 2023, we announced our solution for the supply chain: Pulse by NABP®. Pulse is an inclusive and secure digital platform that simplifies the process of achieving DSCSA compliance. Pulse provides access to user-friendly tools and a comprehensive network of verified relationships, enabling consistent communication with trusted partners across the supply chain from manufacturers to dispensers.
We continue to work with regulators and industry stakeholders to develop this complex platform and roll it out in phases. We have already seen a positive impact with the launch of the Pulse’s product verification service, which helps regulators and other trading partners identify illegitimate products in the supply chain.
We collaborated with industry leaders across the drug supply chain throughout the development of Pulse to ensure that our solution meets industry needs. In addition, we have seen successful application of Pulse in international settings. Our recent report on Operation African Star 2 shares the results of joint efforts in East Africa to keep falsified and illicit products from reaching patients.
Additional Resources
Increasing awareness about state importation programs is necessary to maintain patient safety. More information about prescription drug importation can be found in the below resources.
Watch this video detailing the presidential initiative of 2021-2022 NABP President Caroline D. Juran, BSPharm, DPH (Hon).